Clinical characteristics of immunoglobulin G4–related disease: a prospective study of 118 Chinese patients

To characterize the clinical features of IgG4-related disease (IgG4-RD) in China. A prospective cohort study of IgG4-RD was carried out in Peking Union Medical College Hospital between 2011 and 2013. Patients with newly diagnosed IgG4-RD were enrolled. A total of 118 patients with IgG4-RD were enrol...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 54; no. 11; pp. 1982 - 1990
Main Authors Lin, Wei, Lu, Sha, Chen, Hua, Wu, Qingjun, Fei, Yunyun, Li, Mengtao, Zhang, Xuan, Tian, Xinping, Zheng, Wenjie, Leng, Xiaomei, Xu, Dong, Wang, Qian, Shen, Min, Wang, Li, Li, Jing, Wu, Di, Zhao, Lidan, Wu, Chanyuan, Yang, Yunjiao, Peng, Linyi, Zhou, Jiaxin, Wang, Yu, Sha, Yue, Huang, Xiaoming, Jiao, Yang, Zeng, Xuejun, Shi, Qun, Li, Ping, Zhang, Shulan, Hu, Chaojun, Deng, Chuiwen, Li, Yongzhe, Zhang, Shangzhu, Liu, Jinjing, Su, Jinmei, Hou, Yong, Jiang, Ying, You, Xin, Zhang, Haiting, Yan, Linyi, Zhang, Wen, Zhao, Yan, Zeng, Xiaofeng, Zhang, Fengchun, Lipsky, Peter E.
Format Journal Article
LanguageEnglish
Published England 01.11.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract To characterize the clinical features of IgG4-related disease (IgG4-RD) in China. A prospective cohort study of IgG4-RD was carried out in Peking Union Medical College Hospital between 2011 and 2013. Patients with newly diagnosed IgG4-RD were enrolled. A total of 118 patients with IgG4-RD were enrolled, including 82 males and 36 females, aged 53.1 (s.d. 13.6) years. The most common symptom at onset was lacrimal gland swelling (38/32.2%). A range of organs were involved: 77 patients (65.3%) had lymphadenopathy, 76 (64.4%) had sialadenitis, 60 (50.8%) had dacryoadenitis, 45 (38.1%) had autoimmune pancreatitis, 32 (27.1%) had pulmonary involvement, 31 (26.3%) had periaortitis/retroperitoneal fibrosis, 29 (35.4% of male patients) had prostatitis and 29 (24.6%) had renal involvement. In addition, there were 21 (17.8%) cases of sclerosing cholangitis, 15 (12.7%) of sinusitis and 10 (8.5%) of inflammatory pseudotumour. Uncommon manifestations included mediastinal fibrosis, skin involvement, sclerosing thyroiditis, hypophysitis, orchitis and colitis. Multiple organ involvement was observed in 93 patients, whereas only 4.2% had only a single organ involved. A history of allergy was reported in 73 (61.9%) patients. The serum IgG4 level was elevated in 97.5% and was correlated with the number of organs involved. Most patients were treated with glucocorticoids alone or in combination with immunosuppressive drugs, and the majority usually improved within 3 months. IgG4-RD is a systemic inflammatory and sclerosing disease. Parotid and lacrimal involvement (formerly called Mikulicz's disease), lymphadenopathy and pancreatitis are the most common manifestations. Patients with IgG4-RD showed favourable responses to treatment with glucocorticoids and immunosuppressive agents.
AbstractList OBJECTIVETo characterize the clinical features of IgG4-related disease (IgG4-RD) in China.METHODSA prospective cohort study of IgG4-RD was carried out in Peking Union Medical College Hospital between 2011 and 2013. Patients with newly diagnosed IgG4-RD were enrolled.RESULTSA total of 118 patients with IgG4-RD were enrolled, including 82 males and 36 females, aged 53.1 (s.d. 13.6) years. The most common symptom at onset was lacrimal gland swelling (38/32.2%). A range of organs were involved: 77 patients (65.3%) had lymphadenopathy, 76 (64.4%) had sialadenitis, 60 (50.8%) had dacryoadenitis, 45 (38.1%) had autoimmune pancreatitis, 32 (27.1%) had pulmonary involvement, 31 (26.3%) had periaortitis/retroperitoneal fibrosis, 29 (35.4% of male patients) had prostatitis and 29 (24.6%) had renal involvement. In addition, there were 21 (17.8%) cases of sclerosing cholangitis, 15 (12.7%) of sinusitis and 10 (8.5%) of inflammatory pseudotumour. Uncommon manifestations included mediastinal fibrosis, skin involvement, sclerosing thyroiditis, hypophysitis, orchitis and colitis. Multiple organ involvement was observed in 93 patients, whereas only 4.2% had only a single organ involved. A history of allergy was reported in 73 (61.9%) patients. The serum IgG4 level was elevated in 97.5% and was correlated with the number of organs involved. Most patients were treated with glucocorticoids alone or in combination with immunosuppressive drugs, and the majority usually improved within 3 months.CONCLUSIONIgG4-RD is a systemic inflammatory and sclerosing disease. Parotid and lacrimal involvement (formerly called Mikulicz's disease), lymphadenopathy and pancreatitis are the most common manifestations. Patients with IgG4-RD showed favourable responses to treatment with glucocorticoids and immunosuppressive agents.
To characterize the clinical features of IgG4-related disease (IgG4-RD) in China. A prospective cohort study of IgG4-RD was carried out in Peking Union Medical College Hospital between 2011 and 2013. Patients with newly diagnosed IgG4-RD were enrolled. A total of 118 patients with IgG4-RD were enrolled, including 82 males and 36 females, aged 53.1 (s.d. 13.6) years. The most common symptom at onset was lacrimal gland swelling (38/32.2%). A range of organs were involved: 77 patients (65.3%) had lymphadenopathy, 76 (64.4%) had sialadenitis, 60 (50.8%) had dacryoadenitis, 45 (38.1%) had autoimmune pancreatitis, 32 (27.1%) had pulmonary involvement, 31 (26.3%) had periaortitis/retroperitoneal fibrosis, 29 (35.4% of male patients) had prostatitis and 29 (24.6%) had renal involvement. In addition, there were 21 (17.8%) cases of sclerosing cholangitis, 15 (12.7%) of sinusitis and 10 (8.5%) of inflammatory pseudotumour. Uncommon manifestations included mediastinal fibrosis, skin involvement, sclerosing thyroiditis, hypophysitis, orchitis and colitis. Multiple organ involvement was observed in 93 patients, whereas only 4.2% had only a single organ involved. A history of allergy was reported in 73 (61.9%) patients. The serum IgG4 level was elevated in 97.5% and was correlated with the number of organs involved. Most patients were treated with glucocorticoids alone or in combination with immunosuppressive drugs, and the majority usually improved within 3 months. IgG4-RD is a systemic inflammatory and sclerosing disease. Parotid and lacrimal involvement (formerly called Mikulicz's disease), lymphadenopathy and pancreatitis are the most common manifestations. Patients with IgG4-RD showed favourable responses to treatment with glucocorticoids and immunosuppressive agents.
Author Peng, Linyi
Yan, Linyi
Wang, Li
Zhang, Xuan
Liu, Jinjing
Zhang, Fengchun
Zheng, Wenjie
Hou, Yong
Lin, Wei
Shen, Min
Shi, Qun
Zhou, Jiaxin
Zhang, Shangzhu
You, Xin
Jiao, Yang
Li, Yongzhe
Zeng, Xuejun
Chen, Hua
Zhang, Wen
Zhang, Haiting
Deng, Chuiwen
Lipsky, Peter E.
Yang, Yunjiao
Sha, Yue
Wang, Yu
Li, Mengtao
Li, Ping
Li, Jing
Su, Jinmei
Xu, Dong
Fei, Yunyun
Wu, Di
Zhang, Shulan
Lu, Sha
Tian, Xinping
Wu, Qingjun
Jiang, Ying
Zeng, Xiaofeng
Wu, Chanyuan
Wang, Qian
Huang, Xiaoming
Zhao, Yan
Leng, Xiaomei
Zhao, Lidan
Hu, Chaojun
Author_xml – sequence: 1
  givenname: Wei
  surname: Lin
  fullname: Lin, Wei
– sequence: 2
  givenname: Sha
  surname: Lu
  fullname: Lu, Sha
– sequence: 3
  givenname: Hua
  surname: Chen
  fullname: Chen, Hua
– sequence: 4
  givenname: Qingjun
  surname: Wu
  fullname: Wu, Qingjun
– sequence: 5
  givenname: Yunyun
  surname: Fei
  fullname: Fei, Yunyun
– sequence: 6
  givenname: Mengtao
  surname: Li
  fullname: Li, Mengtao
– sequence: 7
  givenname: Xuan
  surname: Zhang
  fullname: Zhang, Xuan
– sequence: 8
  givenname: Xinping
  surname: Tian
  fullname: Tian, Xinping
– sequence: 9
  givenname: Wenjie
  surname: Zheng
  fullname: Zheng, Wenjie
– sequence: 10
  givenname: Xiaomei
  surname: Leng
  fullname: Leng, Xiaomei
– sequence: 11
  givenname: Dong
  surname: Xu
  fullname: Xu, Dong
– sequence: 12
  givenname: Qian
  surname: Wang
  fullname: Wang, Qian
– sequence: 13
  givenname: Min
  surname: Shen
  fullname: Shen, Min
– sequence: 14
  givenname: Li
  surname: Wang
  fullname: Wang, Li
– sequence: 15
  givenname: Jing
  surname: Li
  fullname: Li, Jing
– sequence: 16
  givenname: Di
  surname: Wu
  fullname: Wu, Di
– sequence: 17
  givenname: Lidan
  surname: Zhao
  fullname: Zhao, Lidan
– sequence: 18
  givenname: Chanyuan
  surname: Wu
  fullname: Wu, Chanyuan
– sequence: 19
  givenname: Yunjiao
  surname: Yang
  fullname: Yang, Yunjiao
– sequence: 20
  givenname: Linyi
  surname: Peng
  fullname: Peng, Linyi
– sequence: 21
  givenname: Jiaxin
  surname: Zhou
  fullname: Zhou, Jiaxin
– sequence: 22
  givenname: Yu
  surname: Wang
  fullname: Wang, Yu
– sequence: 23
  givenname: Yue
  surname: Sha
  fullname: Sha, Yue
– sequence: 24
  givenname: Xiaoming
  surname: Huang
  fullname: Huang, Xiaoming
– sequence: 25
  givenname: Yang
  surname: Jiao
  fullname: Jiao, Yang
– sequence: 26
  givenname: Xuejun
  surname: Zeng
  fullname: Zeng, Xuejun
– sequence: 27
  givenname: Qun
  surname: Shi
  fullname: Shi, Qun
– sequence: 28
  givenname: Ping
  surname: Li
  fullname: Li, Ping
– sequence: 29
  givenname: Shulan
  surname: Zhang
  fullname: Zhang, Shulan
– sequence: 30
  givenname: Chaojun
  surname: Hu
  fullname: Hu, Chaojun
– sequence: 31
  givenname: Chuiwen
  surname: Deng
  fullname: Deng, Chuiwen
– sequence: 32
  givenname: Yongzhe
  surname: Li
  fullname: Li, Yongzhe
– sequence: 33
  givenname: Shangzhu
  surname: Zhang
  fullname: Zhang, Shangzhu
– sequence: 34
  givenname: Jinjing
  surname: Liu
  fullname: Liu, Jinjing
– sequence: 35
  givenname: Jinmei
  surname: Su
  fullname: Su, Jinmei
– sequence: 36
  givenname: Yong
  surname: Hou
  fullname: Hou, Yong
– sequence: 37
  givenname: Ying
  surname: Jiang
  fullname: Jiang, Ying
– sequence: 38
  givenname: Xin
  surname: You
  fullname: You, Xin
– sequence: 39
  givenname: Haiting
  surname: Zhang
  fullname: Zhang, Haiting
– sequence: 40
  givenname: Linyi
  surname: Yan
  fullname: Yan, Linyi
– sequence: 41
  givenname: Wen
  surname: Zhang
  fullname: Zhang, Wen
– sequence: 42
  givenname: Yan
  surname: Zhao
  fullname: Zhao, Yan
– sequence: 43
  givenname: Xiaofeng
  surname: Zeng
  fullname: Zeng, Xiaofeng
– sequence: 44
  givenname: Fengchun
  surname: Zhang
  fullname: Zhang, Fengchun
– sequence: 45
  givenname: Peter E.
  surname: Lipsky
  fullname: Lipsky, Peter E.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26106212$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtOwzAQhi0EolA4ARLykk2oX40TdqjiJVViA-vItSetwYmL7SB1xx24ISchVUuFWLCaWXzfaGb-Y7Tf-hYQOqPkkpKSj8ICukYl7_x8NXqFd0b4HjqiImcZ4Zzt73omBug4xhdCyJjy4hANWE5Jzig7Qm7ibGu1clgvVFA6QbAxWR2xr7Ftmq71c-dnXU_hO_H18RnAqQQGGxtBRbjCCi-Dj0vQyb4Djqkzq7VLaYEnC9tCBLxUyUKb4gk6qJWLcLqtQ_R8e_M0uc-mj3cPk-tppoWgKZNM5GNaQ6nHBeUSQNazWud8LDlVM6MVYZqpUheFFtJwZqCujZGiUFIWRJd8iC42c_vN3jqIqWps1OCcasF3saKSMUHLIpc9er5Fu1kDploG26iwqn4-1AN8A-j-yhig3iGUVOscqt85VJsceqv8Y2mb-i_4NgVl3b_uN8Orlzc
CitedBy_id crossref_primary_10_1016_j_remnie_2021_02_002
crossref_primary_10_1007_s00296_017_3730_5
crossref_primary_10_5582_irdr_2018_01075
crossref_primary_10_1080_14397595_2018_1554321
crossref_primary_10_3171_2016_5_SPINE16119
crossref_primary_10_1016_j_jbspin_2018_01_014
crossref_primary_10_1080_14397595_2016_1233929
crossref_primary_10_1111_odi_13926
crossref_primary_10_1080_14397595_2019_1572575
crossref_primary_10_1016_j_rcreu_2021_04_010
crossref_primary_10_1007_s10067_024_07276_w
crossref_primary_10_1016_j_berh_2016_07_003
crossref_primary_10_1186_s13075_020_02338_1
crossref_primary_10_1093_mr_roac065
crossref_primary_10_1210_clinem_dgab672
crossref_primary_10_1136_bjo_2021_320936
crossref_primary_10_4103_cdr_cdr_90_21
crossref_primary_10_1093_rheumatology_keaa775
crossref_primary_10_1093_rheumatology_keaa411
crossref_primary_10_1111_aos_14048
crossref_primary_10_1097_MPA_0000000000001558
crossref_primary_10_3390_ijms241813735
crossref_primary_10_1001_jamadermatol_2019_4260
crossref_primary_10_1016_j_medcle_2019_10_020
crossref_primary_10_1186_s12882_021_02477_w
crossref_primary_10_1016_j_wneu_2022_12_108
crossref_primary_10_1177_20406223211028776
crossref_primary_10_18786_2072_0505_2020_48_010
crossref_primary_10_1016_j_ajoc_2020_100789
crossref_primary_10_1016_j_medcli_2019_10_026
crossref_primary_10_1111_joim_12942
crossref_primary_10_1038_nrgastro_2016_132
crossref_primary_10_1016_j_jfo_2023_04_007
crossref_primary_10_1007_s00428_021_03216_0
crossref_primary_10_1016_j_heliyon_2023_e23433
crossref_primary_10_1007_s13760_021_01844_6
crossref_primary_10_1093_mrcr_rxae083
crossref_primary_10_1016_j_amjms_2017_08_014
crossref_primary_10_1093_rheumatology_keaa648
crossref_primary_10_1007_s12016_016_8584_1
crossref_primary_10_3390_life13081725
crossref_primary_10_1016_j_jns_2021_117420
crossref_primary_10_1177_11206721221102274
crossref_primary_10_1007_s12020_021_02714_0
crossref_primary_10_1186_s13075_021_02627_3
crossref_primary_10_4103_0366_6999_184459
crossref_primary_10_2169_naika_110_962
crossref_primary_10_1016_j_semarthrit_2019_05_003
crossref_primary_10_1080_14397595_2018_1546367
crossref_primary_10_1111_bpa_12459
crossref_primary_10_1136_bmj_m1067
crossref_primary_10_25259_JSSTD_52_2019
crossref_primary_10_1136_rmdopen_2022_002521
crossref_primary_10_1016_j_gtc_2017_01_001
crossref_primary_10_1111_1756_185X_13088
crossref_primary_10_1111_imj_13430
crossref_primary_10_1016_j_ijom_2023_01_007
crossref_primary_10_1186_s12890_020_01250_3
crossref_primary_10_3343_alm_2023_43_5_461
crossref_primary_10_1016_j_waojou_2023_100864
crossref_primary_10_1080_1744666X_2019_1560268
crossref_primary_10_1186_s12882_020_02223_8
crossref_primary_10_1002_pros_23684
crossref_primary_10_1007_s10067_020_05135_y
crossref_primary_10_1007_s10067_020_05097_1
crossref_primary_10_1053_j_gastro_2018_06_082
crossref_primary_10_1111_joim_13814
crossref_primary_10_2147_CCID_S406199
crossref_primary_10_1016_j_ekir_2018_08_011
crossref_primary_10_1155_2018_7637435
crossref_primary_10_1016_j_jtauto_2020_100074
crossref_primary_10_1111_jne_12942
crossref_primary_10_1016_j_autrev_2021_102805
crossref_primary_10_1186_s13075_019_2090_9
crossref_primary_10_3390_biomedicines11082287
crossref_primary_10_7759_cureus_17940
crossref_primary_10_1093_mr_roac132
crossref_primary_10_1007_s12016_021_08887_w
crossref_primary_10_1002_ccr3_7865
crossref_primary_10_1093_ajcp_aqaa258
crossref_primary_10_1097_CU9_0000000000000097
crossref_primary_10_1093_rheumatology_kez667
crossref_primary_10_1186_s12882_019_1419_6
crossref_primary_10_1097_MD_0000000000006205
crossref_primary_10_1186_s13075_017_1467_x
crossref_primary_10_47360_1995_4484_2020_368_375
crossref_primary_10_1177_2050640620934911
crossref_primary_10_1371_journal_pone_0183844
crossref_primary_10_1016_j_ccm_2019_05_005
crossref_primary_10_1007_s00296_024_05611_7
crossref_primary_10_1186_s13075_017_1507_6
crossref_primary_10_1016_j_wneu_2020_07_227
crossref_primary_10_1111_1756_185X_13949
crossref_primary_10_1007_s12026_019_9070_7
crossref_primary_10_26442_00403660_2019_05_000236
crossref_primary_10_1053_j_semvascsurg_2023_04_019
crossref_primary_10_3389_fimmu_2022_825386
crossref_primary_10_1016_S1773_035X_16_30225_8
crossref_primary_10_1016_j_waojou_2023_100765
crossref_primary_10_1002_ccr3_6324
crossref_primary_10_1080_17446651_2019_1598260
crossref_primary_10_1097_RHU_0000000000000705
crossref_primary_10_1007_s11940_017_0450_9
crossref_primary_10_1016_j_remn_2020_12_001
crossref_primary_10_1007_s00428_024_03757_0
crossref_primary_10_1097_RHU_0000000000002057
crossref_primary_10_1016_j_reuma_2022_11_006
crossref_primary_10_1186_s12890_019_0785_y
crossref_primary_10_1002_rcr2_958
crossref_primary_10_5530_ami_2016_1_44
crossref_primary_10_1016_j_ehpc_2018_05_005
crossref_primary_10_1212_NXI_0000000000000568
crossref_primary_10_1016_j_amjmed_2020_04_040
crossref_primary_10_1186_s13075_018_1567_2
crossref_primary_10_1016_j_cdtm_2017_05_003
crossref_primary_10_1007_s11596_021_2359_5
crossref_primary_10_1016_j_radcr_2016_10_008
crossref_primary_10_1186_s13075_017_1231_2
crossref_primary_10_1016_j_anl_2023_10_006
crossref_primary_10_1007_s11154_018_9480_1
crossref_primary_10_1016_j_rhum_2019_03_010
crossref_primary_10_1186_s12905_022_01968_8
crossref_primary_10_1016_j_gtc_2019_02_008
crossref_primary_10_1155_2023_2742839
crossref_primary_10_1007_s11102_016_0736_z
crossref_primary_10_1016_j_amjms_2020_05_031
crossref_primary_10_1016_j_autrev_2022_103035
crossref_primary_10_3389_fimmu_2022_1077609
crossref_primary_10_1111_ijd_13369
crossref_primary_10_1038_s41575_021_00529_y
crossref_primary_10_1016_j_revmed_2020_06_015
crossref_primary_10_12677_acm_2024_1451403
crossref_primary_10_1097_RHU_0000000000001895
crossref_primary_10_1159_000480297
crossref_primary_10_1038_s41598_020_61585_z
crossref_primary_10_1186_s13075_022_02792_z
crossref_primary_10_3390_endocrines2020016
crossref_primary_10_1016_j_semarthrit_2023_152202
crossref_primary_10_1016_j_beem_2019_04_010
crossref_primary_10_1016_j_jvs_2022_12_024
crossref_primary_10_1155_2021_1959832
crossref_primary_10_1007_s11102_021_01180_1
crossref_primary_10_1016_j_autrev_2016_12_008
crossref_primary_10_1016_j_rcreue_2021_04_007
crossref_primary_10_1016_j_path_2023_01_002
crossref_primary_10_1186_s40792_021_01151_5
crossref_primary_10_1080_14397595_2020_1859710
crossref_primary_10_1017_S0022215118002153
crossref_primary_10_1038_s41598_018_28405_x
crossref_primary_10_5114_reum_2016_63667
crossref_primary_10_1097_PAI_0000000000001040
crossref_primary_10_1007_s11102_018_00930_y
crossref_primary_10_1186_s13023_022_02404_8
crossref_primary_10_1186_s13075_024_03391_w
crossref_primary_10_1016_j_athoracsur_2017_09_018
crossref_primary_10_1111_1759_7714_12914
crossref_primary_10_1016_j_reumae_2023_05_001
crossref_primary_10_1007_s10238_023_01123_z
crossref_primary_10_1111_1756_185X_12863
crossref_primary_10_1155_2018_4057024
crossref_primary_10_1155_2020_5851842
crossref_primary_10_1080_25785826_2024_2430812
crossref_primary_10_7759_cureus_47099
crossref_primary_10_1038_s41598_017_06520_5
Cites_doi 10.1136/ard.2008.089169
10.1038/ki.2013.191
10.1186/ar4571
10.2214/AJR.12.9995
10.3109/03009742.2013.822094
10.1016/j.autrev.2010.05.003
10.1007/s10165-011-0508-6
10.1111/j.1365-2222.2009.03207.x
10.1111/j.1572-0241.2003.08758.x
10.1016/j.anndiagpath.2013.04.010
10.1007/s00535-006-1908-9
10.1016/j.autrev.2004.10.005
10.1056/NEJMra1104650
10.1007/s00259-014-2729-3
10.5402/2011/873087
10.1097/MD.0b013e3182433d77
10.1093/rheumatology/ket182
10.1111/all.12320
10.1159/000336706
10.1016/j.asjsur.2012.04.013
10.1056/NEJM200103083441005
10.1053/j.semdp.2012.08.002
10.1097/MNH.0b013e32835265ac
10.1111/all.12342
10.1007/s12016-014-8430-2
10.1097/PAS.0b013e3181f7266b
10.1038/modpathol.2013.236
10.1164/rccm.201306-1121ED
10.1002/art.33320
10.1016/j.jjcc.2011.10.005
10.1002/lary.22449
10.1016/j.jbspin.2014.01.010
10.1093/rheumatology/keu228
10.1183/09031936.00025211
10.1007/s10165-011-0571-z
ContentType Journal Article
Copyright The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1093/rheumatology/kev203
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1462-0332
EndPage 1990
ExternalDocumentID 26106212
10_1093_rheumatology_kev203
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29P
2WC
354
3O-
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAGKA
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
AAYXX
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNGD
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABVGC
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACPRK
ACUFI
ACUKT
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEHUL
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AGINJ
AGKEF
AGORE
AGQPQ
AGSYK
AGUTN
AHGBF
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQDSO
ATGXG
ATTQO
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CAG
CDBKE
CITATION
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
MHKGH
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RIG
RNI
ROL
ROX
RUSNO
RW1
RXO
RZF
RZO
SV3
TCURE
TEORI
TJX
TMA
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZY1
~91
ABQTQ
CGR
CUY
CVF
ECM
EIF
M49
NPM
7X8
ID FETCH-LOGICAL-c441t-724651fe9c58137ee7fbfc635731abdca02c2a9c88c47d32deffdd748a7780c93
ISSN 1462-0324
IngestDate Fri Jul 11 11:53:52 EDT 2025
Thu Apr 03 07:08:21 EDT 2025
Tue Jul 01 01:36:34 EDT 2025
Thu Apr 24 23:20:41 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords IgG4
autoimmune pancreatitis
prospective cohort
IgG4-related disease
Mikulicz’s disease
Language English
License The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c441t-724651fe9c58137ee7fbfc635731abdca02c2a9c88c47d32deffdd748a7780c93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 26106212
PQID 1722419867
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1722419867
pubmed_primary_26106212
crossref_primary_10_1093_rheumatology_kev203
crossref_citationtrail_10_1093_rheumatology_kev203
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-11-01
PublicationDateYYYYMMDD 2015-11-01
PublicationDate_xml – month: 11
  year: 2015
  text: 2015-11-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Rheumatology (Oxford, England)
PublicationTitleAlternate Rheumatology (Oxford)
PublicationYear 2015
References 2015101306572524000_54.11.1982.20
2015101306572524000_54.11.1982.21
2015101306572524000_54.11.1982.22
2015101306572524000_54.11.1982.23
2015101306572524000_54.11.1982.24
2015101306572524000_54.11.1982.25
2015101306572524000_54.11.1982.26
2015101306572524000_54.11.1982.27
2015101306572524000_54.11.1982.28
2015101306572524000_54.11.1982.29
2015101306572524000_54.11.1982.30
Ebbo (2015101306572524000_54.11.1982.2) 2013; 63
2015101306572524000_54.11.1982.31
2015101306572524000_54.11.1982.10
2015101306572524000_54.11.1982.32
2015101306572524000_54.11.1982.11
2015101306572524000_54.11.1982.33
2015101306572524000_54.11.1982.34
Rollins (2015101306572524000_54.11.1982.12) 2011; 2011
2015101306572524000_54.11.1982.1
2015101306572524000_54.11.1982.4
2015101306572524000_54.11.1982.5
2015101306572524000_54.11.1982.8
2015101306572524000_54.11.1982.13
2015101306572524000_54.11.1982.35
2015101306572524000_54.11.1982.9
2015101306572524000_54.11.1982.14
2015101306572524000_54.11.1982.36
2015101306572524000_54.11.1982.6
2015101306572524000_54.11.1982.15
2015101306572524000_54.11.1982.37
2015101306572524000_54.11.1982.7
2015101306572524000_54.11.1982.16
2015101306572524000_54.11.1982.38
2015101306572524000_54.11.1982.17
2015101306572524000_54.11.1982.18
2015101306572524000_54.11.1982.19
Hirabayashi (2015101306572524000_54.11.1982.3) 2012; 104
References_xml – ident: 2015101306572524000_54.11.1982.26
  doi: 10.1136/ard.2008.089169
– ident: 2015101306572524000_54.11.1982.18
  doi: 10.1038/ki.2013.191
– ident: 2015101306572524000_54.11.1982.31
  doi: 10.1186/ar4571
– ident: 2015101306572524000_54.11.1982.16
  doi: 10.2214/AJR.12.9995
– ident: 2015101306572524000_54.11.1982.23
  doi: 10.3109/03009742.2013.822094
– ident: 2015101306572524000_54.11.1982.7
  doi: 10.1016/j.autrev.2010.05.003
– ident: 2015101306572524000_54.11.1982.9
  doi: 10.1007/s10165-011-0508-6
– ident: 2015101306572524000_54.11.1982.32
  doi: 10.1111/j.1365-2222.2009.03207.x
– ident: 2015101306572524000_54.11.1982.4
  doi: 10.1136/ard.2008.089169
– volume: 63
  start-page: 605
  year: 2013
  ident: 2015101306572524000_54.11.1982.2
  article-title: [IgG4-related disease]
  publication-title: Rev Prat
– ident: 2015101306572524000_54.11.1982.6
  doi: 10.1111/j.1572-0241.2003.08758.x
– ident: 2015101306572524000_54.11.1982.19
  doi: 10.1016/j.anndiagpath.2013.04.010
– ident: 2015101306572524000_54.11.1982.33
  doi: 10.1007/s00535-006-1908-9
– volume: 104
  start-page: 43
  year: 2012
  ident: 2015101306572524000_54.11.1982.3
  article-title: IgG4-related disease
  publication-title: Pathologica
– ident: 2015101306572524000_54.11.1982.8
  doi: 10.1016/j.autrev.2004.10.005
– ident: 2015101306572524000_54.11.1982.1
  doi: 10.1056/NEJMra1104650
– ident: 2015101306572524000_54.11.1982.35
  doi: 10.1007/s00259-014-2729-3
– volume: 2011
  start-page: 873087
  year: 2011
  ident: 2015101306572524000_54.11.1982.12
  article-title: Gastric IgG4-related autoimmune fibrosclerosing pseudotumour: a novel location
  publication-title: ISRN Gastroenterol
  doi: 10.5402/2011/873087
– ident: 2015101306572524000_54.11.1982.25
  doi: 10.1097/MD.0b013e3182433d77
– ident: 2015101306572524000_54.11.1982.34
  doi: 10.1093/rheumatology/ket182
– ident: 2015101306572524000_54.11.1982.27
  doi: 10.1111/all.12320
– ident: 2015101306572524000_54.11.1982.15
  doi: 10.1159/000336706
– ident: 2015101306572524000_54.11.1982.21
  doi: 10.1016/j.asjsur.2012.04.013
– ident: 2015101306572524000_54.11.1982.5
  doi: 10.1056/NEJM200103083441005
– ident: 2015101306572524000_54.11.1982.37
  doi: 10.1053/j.semdp.2012.08.002
– ident: 2015101306572524000_54.11.1982.14
  doi: 10.1097/MNH.0b013e32835265ac
– ident: 2015101306572524000_54.11.1982.30
  doi: 10.1111/all.12342
– ident: 2015101306572524000_54.11.1982.20
  doi: 10.1007/s12016-014-8430-2
– ident: 2015101306572524000_54.11.1982.24
  doi: 10.1097/PAS.0b013e3181f7266b
– ident: 2015101306572524000_54.11.1982.28
  doi: 10.1038/modpathol.2013.236
– ident: 2015101306572524000_54.11.1982.17
  doi: 10.1164/rccm.201306-1121ED
– ident: 2015101306572524000_54.11.1982.29
  doi: 10.1002/art.33320
– ident: 2015101306572524000_54.11.1982.10
  doi: 10.1016/j.jjcc.2011.10.005
– ident: 2015101306572524000_54.11.1982.11
  doi: 10.1002/lary.22449
– ident: 2015101306572524000_54.11.1982.36
  doi: 10.1016/j.jbspin.2014.01.010
– ident: 2015101306572524000_54.11.1982.38
  doi: 10.1093/rheumatology/keu228
– ident: 2015101306572524000_54.11.1982.13
  doi: 10.1183/09031936.00025211
– ident: 2015101306572524000_54.11.1982.22
  doi: 10.1007/s10165-011-0571-z
SSID ssj0005138
Score 2.553059
Snippet To characterize the clinical features of IgG4-related disease (IgG4-RD) in China. A prospective cohort study of IgG4-RD was carried out in Peking Union Medical...
OBJECTIVETo characterize the clinical features of IgG4-related disease (IgG4-RD) in China.METHODSA prospective cohort study of IgG4-RD was carried out in...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1982
SubjectTerms Adult
Aged
Aged, 80 and over
Asian Continental Ancestry Group
China - epidemiology
Cohort Studies
Drug Therapy, Combination
Female
Glucocorticoids - therapeutic use
Humans
Immunoglobulin G
Immunosuppressive Agents - therapeutic use
Incidence
Lymphatic Diseases - epidemiology
Lymphatic Diseases - etiology
Male
Middle Aged
Mikulicz' Disease - epidemiology
Mikulicz' Disease - etiology
Pancreatitis - epidemiology
Pancreatitis - etiology
Prospective Studies
Retrospective Studies
Scleroderma, Systemic - complications
Scleroderma, Systemic - drug therapy
Scleroderma, Systemic - immunology
Treatment Outcome
Title Clinical characteristics of immunoglobulin G4–related disease: a prospective study of 118 Chinese patients
URI https://www.ncbi.nlm.nih.gov/pubmed/26106212
https://www.proquest.com/docview/1722419867
Volume 54
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwELWWIiFeULkvUGQkHkmb2E4c84aq0uVSJFAr-hY5jqOCqizqbiTEE__Qj-C_-BLGt8S7QEV5iXatZKLsnJ1LPHMGoaeiybhsaJGA_a0T1rYskeAokwLwpGrCwCeZbuSDd8XsiL0-zo8nkx9R1VK_rLfVtz_2lfyPVmEN9Gq6ZC-h2UEoLMBn0C8cQcNw_Ccd74a2RrVGu2x4IEzjx9zwfdha830WyhqobV-BONPvzbh2ZzCkoenSUc4aGZAW2AHbeqEDAesijmY_nOgeIl5H42R4S7-GUnk_GyR6z_DWkRV81J-Gld6-ej0Za4V8p8isH32FPec9-NfPfRe_ochy36o3GlVWkCSlrld6W8drdMUSOzrpgLgssquZcCOKvI_OhJsx-pv9d9xYZ9HTw1fQHknp6PDCJv-aHxyqE92-PK1iMZUTcgVdJZCP2Nz91ZuxliizI9OHBw30VoLuxEJ2nJDVEOgveY2Nbw430Q2fmOAXDmU30UR3t9C1A196cRudBrDhNbDheYtXwYb32c_v5x5m2MPsOZY4Ahm2IDPXAsiwBxkOILuDjl7uHe7OEj-qI1EQTy8TTliRZ60WKi8zyrXmbd0qw3VIM1k3SqZEESlUWSrGG0oa3bZNw1kpOS9TJehdtNHNO30fYSppWSjTf8klE2les1JJCHLzJi1IW4spIuHXq5TnsTfjVE6rC_Q2Rc-Gi744GpeLT38S1FKBuTV7aLLT835RQbwPMa8oCz5F95y-BoEEUpECQsEHl7vZQ3R9_Nc8QhvLs15vQaS7rB9blP0CkiCxuw
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+characteristics+of+immunoglobulin+G4%E2%80%93related+disease%3A+a+prospective+study+of+118+Chinese+patients&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Lin%2C+Wei&rft.au=Lu%2C+Sha&rft.au=Chen%2C+Hua&rft.au=Wu%2C+Qingjun&rft.date=2015-11-01&rft.issn=1462-0324&rft.eissn=1462-0332&rft.volume=54&rft.issue=11&rft.spage=1982&rft.epage=1990&rft_id=info:doi/10.1093%2Frheumatology%2Fkev203&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_rheumatology_kev203
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon